Maureen Galmes-Spit
Vice President Research Laigo Bio
Experienced ubiquitin researcher with extensive understanding of ubiquitin biology in the context of oncogenic signaling. Maureen was awarded several grants, including a prestigious KWF (Dutch Cancer Society) personal fellowship for her research at the University College London Cancer Institute (UK) and Leiden University Medical Center (NL) where she focused on ubiquitination in colorectal and ovarian cancer. She obtained her PhD in molecular cell biology at the University Utrecht (NL) in the lab of Madelon Maurice, where she discovered the role of transmembrane E3 ubiquitin ligase RNF43 in stem cells and revealed its molecular mechanism of action. This finding laid the foundation for the development of SureTAC technology. Maureen enjoys good food and music in the company of friends and family in her free time.
Seminars
- Defining key principles for expanding the druggable proteome and identifying targets amenable to novel induced proximity strategies
- Investigating unmet needs where emerging modalities outperform traditional degradation and uncovering new therapeutic niches
- Addressing translational hurdles for novel approaches and highlighting biotech priorities in overcoming delivery, specificity and scalability challenges
- Spotlighting the most exciting new directions in induced proximity, from novel E3 ligases to non-degradative functional modulation
- Developing bispecific SureTAC antibodies that drive internalization and degradation of membrane proteins in a tissue- and disease-specific manner
- Harnessing the TED-I screening platform to identify high-potency E3–target pairs for enhanced degradation efficiency
- Demonstrating translational potential with preclinical data validating selective degradation of challenging membrane targets
